Arbutus Biopharma (ABUS) Long-Term Deferred Tax (2012 - 2014)

Arbutus Biopharma (ABUS) has reported Long-Term Deferred Tax for 3 consecutive years, with $4491.0 the latest figure, recorded in Q4 2014.

• Quarterly Long-Term Deferred Tax rose 3.15% year-over-year to $4491.0 in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $4491.0 (up 3.15% YoY) and the FY2014 annual result came in at $4491.0, up 3.15% from the prior year.
• Long-Term Deferred Tax climbed to $4491.0 in Q4 2014 per ABUS's latest filing, from $4354.0 in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for ABUS reached as high as $49.9 million in Q4 2012 and fell as low as $4354.0 in Q4 2013.
• A 3-year average of $16.6 million and a median of $4491.0 in 2014 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2013 — Long-Term Deferred Tax slumped 99.99% — and 2014, when it advanced 3.15%.
• Year by year, Long-Term Deferred Tax stood at $49.9 million in 2012, then sank by 99.99% to $4354.0 in 2013, then advanced by 3.15% to $4491.0 in 2014.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $4491.0, $4354.0, and $49.9 million for Q4 2014, Q4 2013, and Q4 2012 respectively.